Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | ALK rearrange CD274 over exp |
Gene Variant Detail | |
Relevant Treatment Approaches |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
ALK rearrange CD274 over exp | lung adenocarcinoma | predicted - sensitive | Atezolizumab + Bevacizumab + Carboplatin + Pemetrexed Disodium | Case Reports/Case Series | Actionable | In a clinical case study, a patient with ALK-rearranged lung adenocarcinoma with high CD274 (PD-L1) expression (TPS>=50%) who progressed on 3 prior ALK inhibitors experienced a rapid and ongoing clinical improvement with the combination therapy of Tecentriq (atezolizumab), Avastin (bevacizumab), Paraplatin (carboplatin), and Alimta (Pemetrexed Disodium), achieving decreased lung lesion size, complete metabolic response of liver lesions, and partial response of bone lesions (PMID: 34336591). | 34336591 |